StockData
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. (ZBIO) stock

ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$26.42−1.33 (-4.79%)

Close on Nov 18, 2026Market cap $1.72BP/E –Yield –

Zenas BioPharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Zenas BioPharma's operating income for the twelve months ending Sep 30, 2026 was -$526.40M. For fiscal 2025 it was -$383.06M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$383.06M–
FY2024Dec 31, 2024-$163.89M–
FY2023Dec 31, 2023-$37.15M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$103.41M–
Q2 FY2026Jun 30, 2026-$107.66M–
Q1 FY2026Mar 31, 2026-$77.35M–
Q4 FY2025Dec 31, 2025-$237.98M–
Q3 FY2025Sep 30, 2025-$52.58M–
Q2 FY2025Jun 30, 2025-$55.16M–
Q1 FY2025Mar 31, 2025-$37.33M–
Q4 FY2024Dec 31, 2024-$55.62M–
Q3 FY2024Sep 30, 2024-$40.98M-215.0%
Q2 FY2024Jun 30, 2024-$39.70M–
Q1 FY2024Mar 31, 2024-$27.58M–
Q4 FY2023Dec 31, 2023-$24.78M–
Q3 FY2023Sep 30, 2023$35.62M–

More Zenas BioPharma figures

See a number that looks wrong?